Technology
Health
Biotechnology

Deciphera Pharmaceuticals

$24.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (0.22%) Today
+$0.05 (0.22%) Today

Why Robinhood?

You can buy or sell DCPH and other stocks, options, ETFs, and crypto commission-free!

About

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. Read More It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Employees
114
Headquarters
Waltham, Massachusetts
Founded
2003
Market Cap
937.40M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
233.83K
High Today
$25.19
Low Today
$24.94
Open Price
$25.00
Volume
6.26K
52 Week High
$45.61
52 Week Low
$18.55

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2017 IPO
US
North America

News

Seeking AlphaMar 4

Deciphera chief to retire March 18

Deciphera Pharmaceuticals (NASDAQ:DCPH) President & CEO Michael Taylor, Ph.D. will retire effective March 18 and transition to an advisory role for six months.

12

Earnings

-$5.85
-$4.05
-$2.26
-$0.46
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.73 per share
Actual
-$0.86 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.